HEALEY ALS Platform Trial

Weekly Q&A – March 17, 2022

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General







































Guest Speaker

Edward Kasarskis, MD, PhD
Platform Trial Site Principal Investigator
University of Kentucky, Lexington KY



University of Kentucky ALS Center

Edward J. Kasarskis MD, PhD

Cynthia Shaw Crispen Chair for ALS Research

Professor, Neurology





Where Are We?











Who Are We?



Edward J. Kasarskis



Deborah Taylor





Vish Kumaraswamy






Other ALS Research at UK

- Nutrition in ALS
 - Rup Tandan; University of Vermont
- FUS familial ALS
 - Haining Zhu; University of Arizona
 - Ziyuan Guo; University of Cincinnati





The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Enrollment Updates (as of March 17, 2022)

• 15 individuals have signed informed consent

8 individuals have been randomized within Regimen E




This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

18 Sites Currently Activated for Regimen E



(as of 3/17/22)

- Lehigh Valley Health Network
 - Mass General Hospital
 - ☑ University of Kansas
 - University of Maryland
 - ☑ California Pacific Medical Center
 - ✓ Northwestern University
 - Virginia Commonwealth University
 - ☑ University of Nebraska
 - **W** Washington University
 - Wake Forest University
 - Mospital for Special Care
 - Saint Alphonsus Regional
 - University of Massachusetts
 - ☑ Duke University
 - ☑ Barrow Neurological Institute
 - **Georgetown University**

 - Market Performance Beth Israel Deaconess Medical Center

Sites in blue participated in previous regimens. Sites in green (also underlined above) are new additions to the Platform Trial!

Regimen E Site Activation

Sites closest to activation:

- ➤ Spectrum Health
- ➤ University of Colorado
- ➤ SUNY Upstate
- ➤ Henry Ford Hospital
- ➤ University of South Florida

- ➤ Providence Brain and Spine
- ➤ Ohio State University
- >Essentia Health
- ➤ University of Cincinnati

Checking Site Status Online

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants in regimen E.

Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.

Site	State	Enrollment Status	Contact Information
Jefferson Weinberg ALS Center, Thomas Jefferson University	PA	Active, Not recruiting	Stephanie Hansen
Lehigh Valley Health Network	PA	Recruiting	Andrew Orzel (610-402-9543)
Penn State Hershey	PA	Active, Not recruiting	Heidi Runk



 $\underline{https://bit.ly/3g2NZr5}$



The ALS Association/Northeast ALS Consortium Educational Webinar

The Latest on Expanded Access Protocols in ALS











Moderator: Jinsy A. Andrews, MD, MSc, Columbia University Medical Center Panelists: Merit Cudkowicz, MD, MSc, Sean M. Healey & AMG Center for ALS at Mass General Hospital, Sabrina Paganoni, MD, PhD, Sean M. Healey & AMG Center for ALS at Mass General Hospital, Philip Green, and Sandy Morris **Register Below:**



https://bit.ly/3COyFZN

Recording will later be available under "educational webinars" on neals.org

Friday, March 18, 2022 12:00 - 1:00 PM EDT

Patient Navigation Central resource for people living with ALS



Catherine Small



Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:



https://bit.ly/3r6Nd2L

ALS Link sign-up:




https://bit.ly/3o2Ds3m

Upcoming Guest Speaker:

March 24th- Jaimin Shah, MD (Mayo Clinic, Jacksonville FL)

Send us webinar questions and ideas!

Travel around the
US meeting
Platform Trial Site
Investigators





Guest speakers from partner foundations

Trehalose/SLS-005
drug science and
mechanism of action
webinar with Seelos
Therapeutics





Special Topics:
Biomarkers, EAPs,
Biostats, Science
topics (epigenetics,
epidemiology)